Voyager Therapeutics (United States)

company in Cambridge, United States

VYGR Nasdaq SEC CIK 1640266
Follow Voyager Therapeutics (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $4M −70% vs same quarter last year
Net income −$24.7M +11.5% vs same quarter last year
EPS, diluted −$0.40 +14.9% vs same quarter last year
Operating cash flow −$19.7M +36.7% vs same quarter last year
Revenue by quarter
$6.3M
$6.5M
$5.2M
$13.4M
$15.3M
$2.6M
$3.2M
$4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income13 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100M$200M$300MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$40.4M−$119.7M
FY24$80M−$65M
FY23$250M$132.3M
FY22$40.9M−$46.4M
FY21$37.4M−$71.2M
FY20$171.1M$36.7M
FY19$104.4M−$43.6M
FY18$7.6M−$88.3M
FY17$10.1M−$70.7M
FY16$14.2M−$40.2M
FY15$17.3M-
FY14--
FY13--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−326.6%−296.5%
FY24−104.1%−81.3%
FY2348.8%52.9%
FY22−124.3%−113.4%
FY21−196.8%−190.3%
FY2016%21.5%
FY19−49.5%−41.8%
FY18−1195.6%−1158.8%
FY17−709.1%−697.6%
FY16−290.4%−282.7%
FY15−116.8%-
FY14--
FY13--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$135.1M
FY24−$18.8M
FY23$74.7M
FY22−$15M
FY21−$55.1M
FY20−$108.8M
FY19$40.9M
FY18−$20.2M
FY17−$65.3M
FY16−$47.5M
FY15$40.3M
FY14−$14.9M
FY13-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Voyager Therapeutics (United States)
  • Healthcare median
−1500%−1000%−500%0%500%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearVoyager Therapeutics (United States)Healthcare median
FY25−296.5%−30.6%
FY24−81.3%−47%
FY2352.9%−58%
FY22−113.4%−80.4%
FY21−190.3%−71.8%
FY2021.5%−62.2%
FY19−41.8%−46.2%
FY18−1158.8%−49.6%
FY17−697.6%−45.9%
FY16−282.7%−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%